Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cassava Sciences Inc (FLNA) vs Matson Inc (MATX) Price & Performance

Cassava Sciences IncTrade
Matson IncTrade

Price performance (Past 24H)

Key statistics

Cassava Sciences Inc vs Matson Inc — how do they compare? Cassava Sciences Inc trades at $0.95 (market cap $47.75M), while Matson Inc trades at $213.58 (market cap $6.11B). The key difference: Matson Inc is far larger — about 128× Cassava Sciences Inc's market cap, and Matson Inc pays a 0.74% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.

FLNAMATX
Market Cap
$47.75M$6.11B
Sector
HealthTechnology
52-Week High
$4.64$223.55
52-Week Low
$0.87$88.05
Enterprise Value
-$34.93M$6.71B
Dividend Yield
0.74%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cassava Sciences Inc

FLNA trades at $0.9528, down 4.46% today, with a bearish technical outlook but strong analyst support (66.7% buy ratings). The company continues to post net losses and negative cash flows, though recent EPS beats show some operational improvement. Recent news highlights Q2 2026 results and business updates on Tuberous Sclerosis Complex therapies.

The outlook remains speculative due to persistent unprofitability and cash burn, but analyst optimism and a low P/B ratio of 0.75 may attract value investors. Key risks include execution challenges in drug development and reliance on financing amid negative earnings.

Matson Inc

Matson (MATX) trades at $212.05, up 1.61% on the day, with a bullish technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $4.27 surpassing expectations. Revenue and net income are trending upward, supported by a robust China service and resilient consumer demand. The company's valuation ratios, including a P/E of 13.79 and EV/EBITDA of 7.78, appear reasonable relative to earnings growth.

The outlook for MATX is positive, driven by earnings momentum and a favorable analyst consensus with a $265 price target implying significant upside. Key opportunities include continued trade flow strength and dividend growth, while risks involve Trans-Pacific trade volatility and broader economic pressures. The stock presents a compelling case for growth-oriented investors seeking exposure to niche shipping services.

Returns comparison

Trailing returns across standard periods

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA

About Matson Inc

Matson, Inc. is an American shipping and logistics company primarily operating in the Pacific. The company provides ocean transportation services, including container, automobile, and general cargo, particularly between the U.S. West Coast, Hawaii, Alaska, and Guam. Matson also offers logistics services, including warehousing, less-than-container load (LCL) consolidation, and supply chain management, making it a critical service provider for businesses operating across the Pacific region.

Read more on MATX